Drugging ATR: progress in the development of specific inhibitors for the treatment of cancer
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Drugging ATR: progress in the development of specific inhibitors for the treatment of cancer
Authors
Keywords
-
Journal
Future Medicinal Chemistry
Volume 7, Issue 7, Pages 873-891
Publisher
Future Science, LTD
Online
2015-06-10
DOI
10.4155/fmc.15.33
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970
- (2015) Amy B. Hall et al. Oncotarget
- Identification of ATR-Chk1 Pathway Inhibitors That Selectively Target p53-Deficient Cells without Directly Suppressing ATR Catalytic Activity
- (2014) M. Kawasumi et al. CANCER RESEARCH
- ATR Inhibitors VE-821 and VX-970 Sensitize Cancer Cells to Topoisomerase I Inhibitors by Disabling DNA Replication Initiation and Fork Elongation Responses
- (2014) R. Josse et al. CANCER RESEARCH
- Phosphatidylinositol 3-Kinase (PI3K) and Phosphatidylinositol 3-Kinase-Related Kinase (PIKK) Inhibitors: Importance of the Morpholine Ring
- (2014) Martin Andrs et al. JOURNAL OF MEDICINAL CHEMISTRY
- A Synthetic Lethal Screen Reveals Enhanced Sensitivity to ATR Inhibitor Treatment in Mantle Cell Lymphoma with ATM Loss-of-Function
- (2014) Daniel L. Menezes et al. MOLECULAR CANCER RESEARCH
- Development of pharmacodynamic biomarkers for ATR inhibitors
- (2014) Tao Chen et al. Molecular Oncology
- General synthetic strategies towards N-alkyl sulfoximine building blocks for medicinal chemistry and the use of dimethylsulfoximine as a versatile precursor
- (2014) Frederick W. Goldberg et al. TETRAHEDRON
- Structure-Based Drug Design of Novel, Potent, and Selective Azabenzimidazoles (ABI) as ATR Inhibitors
- (2014) Paul A Barsanti et al. ACS Medicinal Chemistry Letters
- Structure-Based Drug Design of Novel Potent and Selective Tetrahydropyrazolo[1,5-a]pyrazines as ATR Inhibitors
- (2014) Paul A Barsanti et al. ACS Medicinal Chemistry Letters
- Sulfoximines: A Neglected Opportunity in Medicinal Chemistry
- (2013) Ulrich Lücking ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATR
- (2013) Q. Liu et al. CANCER RESEARCH
- Targeting ATR in DNA damage response and cancer therapeutics
- (2013) Emmanouil Fokas et al. CANCER TREATMENT REVIEWS
- Wee1 kinase as a target for cancer therapy
- (2013) Khanh Do et al. CELL CYCLE
- The Lab Oddity Prevails: Discovery of Pan-CDK Inhibitor (R)-S-Cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide (BAY 1000394) for the Treatment of Cancer
- (2013) Ulrich Lücking et al. ChemMedChem
- Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): A Potent and Selective Inhibitor of ATR Protein Kinase with Monotherapy in Vivo Antitumor Activity
- (2013) Kevin M. Foote et al. JOURNAL OF MEDICINAL CHEMISTRY
- mTOR kinase structure, mechanism and regulation
- (2013) Haijuan Yang et al. NATURE
- The ATM protein kinase: regulating the cellular response to genotoxic stress and more
- (2013) Yosef Shiloh et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- ATM signalling and cancer
- (2013) C A Cremona et al. ONCOGENE
- Modulation of DNA repair by pharmacological inhibitors of the PIKK protein kinase family
- (2012) M. Raymond V. Finlay et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Sulfonyl-morpholino-pyrimidines: SAR and development of a novel class of selective mTOR kinase inhibitor
- (2012) M. Raymond V. Finlay et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy
- (2012) Remko Prevo et al. CANCER BIOLOGY & THERAPY
- Discovery of Novel Potent and Highly Selective Glycogen Synthase Kinase-3β (GSK3β) Inhibitors for Alzheimer’s Disease: Design, Synthesis, and Characterization of Pyrazines
- (2012) Stefan Berg et al. JOURNAL OF MEDICINAL CHEMISTRY
- Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation
- (2012) E Fokas et al. Cell Death & Disease
- ATR signalling: more than meeting at the fork
- (2011) Edward A. Nam et al. BIOCHEMICAL JOURNAL
- Phylogenomics of phosphoinositide lipid kinases: perspectives on the evolution of second messenger signaling and drug discovery
- (2011) James R Brown et al. BMC EVOLUTIONARY BIOLOGY
- Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines
- (2011) A Peasland et al. BRITISH JOURNAL OF CANCER
- Targeting the S and G2 checkpoint to treat cancer
- (2011) Tao Chen et al. DRUG DISCOVERY TODAY
- Discovery of 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a Potent, Selective, and Orally Available Mammalian Target of Rapamycin (mTOR) Inhibitor for Treatment of Cancer
- (2011) Qingsong Liu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase as Potential Anticancer Agents
- (2011) Jean-Damien Charrier et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
- (2011) J. Jean Cui et al. JOURNAL OF MEDICINAL CHEMISTRY
- Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR
- (2011) Philip M Reaper et al. Nature Chemical Biology
- Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors
- (2011) Matilde Murga et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations
- (2011) Luis I Toledo et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Chemical methodology as a source of small-molecule checkpoint inhibitors and heat shock protein 70 (Hsp70) modulators
- (2011) D. M. Huryn et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Combining ATR Suppression with Oncogenic Ras Synergistically Increases Genomic Instability, Causing Synthetic Lethality or Tumorigenesis in a Dosage-Dependent Manner
- (2010) O. Gilad et al. CANCER RESEARCH
- The DNA-dependent protein kinase (DNA-PK): More than just a case of making ends meet?
- (2010) Richard Hill et al. CELL CYCLE
- The DNA-damage response in human biology and disease
- (2009) Stephen P. Jackson et al. NATURE
- Inhibition of ATR protein kinase activity by schisandrin B in DNA damage response
- (2009) H. Nishida et al. NUCLEIC ACIDS RESEARCH
- Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
- (2008) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
- ATR: an essential regulator of genome integrity
- (2008) Karlene A. Cimprich et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started